# Building a pharma data governancedata governanceData governance is the set of policies, roles, and processes that ensure data is accurate, secure, well-defined, and used responsibly across an organization.View full definition → operating model
Picture a data governancedata governanceData governance is the set of policies, roles, and processes that ensure data is accurate, secure, well-defined, and used responsibly across an organization.View full definition → council meeting at a mid-size pharma company in 2026. Item one: who owns the HCP (Health Care Professional) engagement data generated when a sales rep logs a conversation with a cardiologist into the ( system)? Item two: who owns the biomarker data pulled from a Phase II trial's blood samples, now sitting in a lab information system?
These sound like similar "who owns the data" questions. They are not. The HCP engagement data is jointly claimed by Commercial (which needs it for targeting) and Medical Affairs (which needs it for compliance review of promotional interactions). The biomarker data is claimed by R&D (which needs it for the primary endpoint analysis) and increasingly by Commercial (which wants early biomarker signals for launch planning).
The council's job is not to pick a single "owner" in the IT sense. It is to assign data stewardshipdata stewardshipA business-side owner responsible for the quality, consistency and appropriate use of data in their domain.View full definition → (the operational responsibility for data qualitydata qualityThe degree to which data is fit for purpose: accurate, complete, consistent, timely, valid and unique. Poor quality data undermines analytics, reporting and AI.View full definition →, access rules and lifecycle), separate from data ownership (the accountability for how the data is used), and to document both in a policy the whole company can audit against.
Pharma sits at the intersection of the strictest privacy regimes and the strictest product regulations. A data governancedata governanceData governance is the set of policies, roles, and processes that ensure data is accurate, secure, well-defined, and used responsibly across an organization.View full definition → operating model is the concrete structure (roles, committees, tools, review cadences) that makes policy enforceable day to day.
Three regulatory forces make this non-optional:
Layer onto this the EU's Clinical Trials Regulation (536/2014) and the FDA's data integrity guidance, and you see why "who can touch this dataset, and how do we prove it" is a board-level question, not just an IT ticket.
A working operating model needs named roles, not just a policy statement. The standard pharma structure looks like this:
Data Owner: A senior business leader (e.g., VPVPA clear statement of the benefits your product delivers, the problems it solves and why customers should choose you over alternatives.View full definition → of Clinical Operations, VPVPA clear statement of the benefits your product delivers, the problems it solves and why customers should choose you over alternatives.View full definition → of Commercial Analytics) accountable for a domain's data. Owners approve access policies and sign off on new uses.
Data StewardData StewardA business-side owner responsible for the quality, consistency and appropriate use of data in their domain.View full definition →: An operational role (often embedded in the function, not IT) who manages day-to-day data qualitydata qualityThe degree to which data is fit for purpose: accurate, complete, consistent, timely, valid and unique. Poor quality data undermines analytics, reporting and AI.View full definition →, metadata, and access requests. A clinical data stewarddata stewardA business-side owner responsible for the quality, consistency and appropriate use of data in their domain.View full definition → ensures trial datasets are clean before a database lock; a commercial data stewarddata stewardA business-side owner responsible for the quality, consistency and appropriate use of data in their domain.View full definition → ensures HCP records are deduplicated and consent flags are current.
Data Governance Council: A cross-functional body, typically including R&D, Medical, Commercial, Legal, Privacy/Compliance and IT, meeting monthly or quarterly to resolve disputes (like the HCP-vs-biomarker example above) and approve new data-sharing agreements.
Data Protection Officer (DPO): A legally mandated role under GDPR for many pharma companies, independent of operational data owners, responsible for privacy compliance oversight.
Qualified Person / Data Integrity Lead: In GxP (Good Practice, e.g. Good Clinical Practice, Good Manufacturing Practice) contexts, a role accountable for ensuring data supporting regulatory filings meets ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available).
A practical governance model defines access tiers tied to role and purpose, not just seniority. A common structure:
| Tier | Who | Example Access |
|---|---|---|
| Tier 1: Identified | Trial site staff, treating physicians | Full patient identifiers, needed for safety follow-up |
| Tier 2: Pseudonymized | Biostatisticians, data managers | Subject IDs replace names; re-identification possible only via a separate key |
| Tier 3: Aggregated/De-identified | Commercial analytics, market access | Cohort-level summaries, no individual-level re-identification risk |
| Tier 4: Public/Synthetic | External partners, academic collaborators | Synthetic or fully anonymized datasets |
This tiering is what makes a data-sharing agreement (DSA) enforceable. A DSA is a contract specifying what data moves between two parties (say, a pharma company and an academic hospital running a real-world evidence study), under what tier, for what purpose, and for how long. Every DSA should mapmapUsing software to automate repetitive marketing tasks and campaigns, enabling personalisation at scale across channels like email, web, and social.View full definition → explicitly to one of these tiers rather than using vague language like "de-identified data" without defining the standard used (HIPAA Safe Harbor and the EMA's anonymization guidance differ in specifics).
Say a market access team requests HCP prescribing patterns linked to real-world outcomes data to build a value dossier for payers. The governance workflow:
1. Request submitted to the relevant Data StewardData StewardA business-side owner responsible for the quality, consistency and appropriate use of data in their domain.View full definition → (Commercial Analytics).
2. Steward checks: does this require Tier 2 (pseudonymized, needs DPO sign-off) or can Tier 3 (aggregated) satisfy the business need?
3. If Tier 2 is genuinely required, request escalates to the Data GovernanceData GovernanceData governance is the set of policies, roles, and processes that ensure data is accurate, secure, well-defined, and used responsibly across an organization.View full definition → Council with a documented purpose limitation (GDPR Article 5 principle: data collected for one purpose cannot be freely repurposed).
4. Legal reviews against existing DSAs with the data source (e.g., a claims data vendor like IQVIA or a health system).
5. Access granted with an expiry date and logged in an access registry, auditable later.
A simple access-control snippet illustrating the logic a governance team might codify in an access-request system:
def evaluate_request(purpose, data_tier_requested, requester_role):
if data_tier_requested == "Tier1_Identified" and requester_role not in ["trial_site_staff", "treating_physician"]:
return "DENY: identified data restricted to clinical care roles"
if purpose not in APPROVED_PURPOSES[data_tier_requested]:
return "ESCALATE: purpose not pre-approved, route to Governance Council"
return "APPROVE: log access, set 12-month expiry"This is illustrative logic, not a real compliance engine, but it shows how governance decisions get operationalized into system rules rather than living only in a policy document.
A governance model is only as good as its audit trail. Practical checks pharma teams run:
The UK's ICO guidance on data protection by design is a good free reference for structuring these audits even outside the UK, since many pharma companies apply one global standard.
Knowledge check
1. In the pharma data governance operating model described, what is the key distinction between data stewardship and data ownership?
2. Why can't the governance council simply assign a single 'owner' to a dataset like HCP engagement data the way IT systems typically assign a system owner?
3. Why is a formal operating model (roles, committees, tools, review cadences) necessary in pharma beyond having a written data governance policy?
4. Select ALL correct answers about why biomarker data from a Phase II trial creates governance complexity similar to (but distinct from) HCP engagement data.
Select all the correct answers.
5. Select ALL correct answers about the regulatory forces that make a formal data governance operating model non-optional for pharma companies.
Select all the correct answers.
The most common failure mode is not malice, it is ambiguity. Commercial teams reuse trial biomarker signals for launch targeting without re-checking whether the original patient consent covered secondary commercial use. R&D teams sit on real-world data that Medical Affairs needs for a safety signal review, because no one formally assigned stewardship when the data source was onboarded.
Good governance councils fix this by requiring a data use case register at intake: every new data source gets a documented owner, steward, allowed purposes and tier, before the first analyst touches it, not after a problem surfaces.